Published in Leukemia on July 17, 2012
New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood (2015) 1.33
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood (2015) 0.97
Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2013) 0.91
Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma. Am J Hematol (2016) 0.84
Deep Response in Multiple Myeloma: A Critical Review. Biomed Res Int (2015) 0.84
A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. Br J Haematol (2016) 0.80
Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio. J Clin Med Res (2016) 0.80
High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. J Hematol Oncol (2015) 0.80
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. Clin J Am Soc Nephrol (2016) 0.77
Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland. Case Rep Hematol (2015) 0.77
Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. Oncol Lett (2016) 0.75
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol (2016) 0.75
Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma. Eur J Haematol (2017) 0.75
Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma. Cancer Sci (2016) 0.75
Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients. Croat Med J (2015) 0.75
Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. Transl Oncol (2017) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia (2008) 8.85
Metabolism of immunoglobulins. Prog Allergy (1969) 5.74
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91
A 71-year-old woman with multiple myeloma status after stem cell transplantation. Clin Chem (2011) 2.25
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem (2009) 1.99
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol (2011) 1.78
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol (2007) 1.62
Appraisal of immunoglobulin free light chain as a marker of response. Blood (2008) 1.38
Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom (2010) 1.36
Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica (2010) 1.14
Immunosuppression and infection in multiple myeloma. Semin Oncol (1986) 1.10
Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem (2009) 0.97
Clonal evolution of myeloma cells leads to quantitative changes in immunoglobulin secretion and surface antigen expression. Proc Natl Acad Sci U S A (1979) 0.97
Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China. Cell Mol Immunol (2008) 0.83
Relationship between serum viscosity and intravascular IgA polymer concentration in IgA myeloma. Clin Exp Immunol (1981) 0.83
Overestimation of monoclonal immunoglobulin by immunochemical methods. Ann Clin Biochem (1991) 0.83
Robust alternatives to traditional analysis of variance: Welch W*, James J I*, James J II*, Brown-Forsythe BF*. Comput Methods Programs Biomed (1988) 0.81
Novel M-component based biomarkers in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk (2011) 0.80
Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet (1993) 3.42
Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood (2001) 2.93
Structure, function and properties of antibody binding sites. J Mol Biol (1991) 2.84
Serum free light chains for monitoring multiple myeloma. Br J Haematol (2004) 2.07
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet (1998) 2.06
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood (1998) 1.90
Localisation of tumour deposits by external scanning after injection of radiolabelled anti-carcinoembryonic antigen. Br Med J (1980) 1.82
Low plasma C4 concentrations: association with microangiopathy in insulin dependent diabetes. Br Med J (Clin Res Ed) (1984) 1.82
A study of plasma proteins in the sol phase of sputum from patients with chronic bronchitis. Thorax (1979) 1.79
Identification of susceptibility loci for insulin-dependent diabetes mellitus by trans-racial gene mapping. Nature (1989) 1.64
Effect of carbon dioxide in acute mountain sickness: a rediscovery. Lancet (1988) 1.64
Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol (2003) 1.55
Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol (1999) 1.47
Indirect detection of intraoperative carbon monoxide exposure by mass spectrometry during isoflurane anesthesia. Anesthesiology (1995) 1.44
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res (1989) 1.35
Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat Rev (1987) 1.31
The clinical assessment of acute mountain sickness. Q J Med (1985) 1.28
Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab (2003) 1.24
The effect of acetazolamide on the proteinuria of altitude. Aviat Space Environ Med (1982) 1.23
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia (2006) 1.22
Altitude insomnia: studies during an expedition to the Himalayas. Sleep (1988) 1.21
Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol (2013) 1.19
Limitations to the killing of tumours using radiolabelled antibodies. Br J Radiol (1987) 1.13
Improved tumour localisation using indium-111 labelled antibodies. Br Med J (Clin Res Ed) (1983) 1.12
Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood (1996) 1.11
Placental iodothyronine deiodinase expression in normal and growth-restricted human pregnancies. J Clin Endocrinol Metab (2003) 1.09
Effect of exercise on cerebral perfusion in humans at high altitude. J Appl Physiol (1985) (2005) 1.09
Methazolamide and acetazolamide in acute mountain sickness. Aviat Space Environ Med (1983) 1.09
Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet (1986) 1.09
Effect of acetazolamide on blood gases and 2,3 DPG during ascent and acclimatization to high altitude. Postgrad Med J (1987) 1.05
Detection of thyroid tumours using radio-labelled anti-thyroglobulin. Clin Endocrinol (Oxf) (1983) 1.05
Explaining the unexpected abnormal results of biochemical profile investigations. Lancet (1974) 1.04
Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol (2010) 1.04
Plasma D-lactate as a potential early marker for colon ischaemia after open aortic reconstruction. Eur J Vasc Endovasc Surg (2005) 1.04
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia (2010) 1.03
Phenotypes of the heavy chains of immunoglobulins in patients with diabetic microangiopathy: evidence for an immunogenetic predisposition. Br Med J (Clin Res Ed) (1986) 1.02
Preparation of a monospecific antiserum to thyroxine binding globulin for its quantitation by rocket immunoelectrophoresis. Clin Chim Acta (1976) 1.01
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia (2007) 0.99
Blood lactate changes during exercise at high altitude. Postgrad Med J (1987) 0.99
The origin of proteinuria at high altitude. Postgrad Med J (1987) 0.98
The Environmental Symptoms Questionnaire in acute mountain sickness. Aviat Space Environ Med (1985) 0.98
Identification of susceptibility loci for type 1 (insulin-dependent) diabetes by trans-racial gene mapping. Diabetologia (1990) 0.97
Measurement of human serum IgE and IgA by reverse passive antiglobulin haemagglutination. Int Arch Allergy Appl Immunol (1981) 0.95
Trans-racial studies implicate HLA-DQ as a component of genetic susceptibility to type 1 (insulin-dependent) diabetes. Diabetologia (1988) 0.94
Aneuploidy of chromosome 8 as detected by interphase fluorescence in situ hybridization is a recurrent finding in primary and metastatic breast cancer. Breast Cancer Res Treat (1998) 0.94
Studies on the developmental expression of glutathione S-transferase isoenzymes in human heart and diaphragm. Biochim Biophys Acta (1987) 0.93
Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using immunoassays specific for free immunoglobulin light chains. Clin Lab (2003) 0.93
Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. Hum Pathol (2000) 0.93
A case of bone marrow mastocytosis associated with multiple myeloma. Ann Hematol (1998) 0.92
Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma--a report on two cases. Ann Hematol (2001) 0.92
Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol (2000) 0.92
Cerebral blood flow in acute mountain sickness. J Appl Physiol (1985) (1990) 0.92
Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia (2000) 0.90
Exome sequencing in tracking clonal evolution in multiple myeloma following therapy. Leukemia (2012) 0.89
Estimation of the Stokes radii of serum proteins for a study of protein movement from blood to amniotic fluid. Biochim Biophys Acta (1976) 0.89
IgG subclasses in systemic lupus erythematosus and other autoimmune rheumatic diseases. Lupus (1992) 0.88
Improved radioimmunodetection of tumours using second antibody. Lancet (1983) 0.88
Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab (2004) 0.88
Localisation of malignant germ-cell tumours by external scanning after injection of radiolabelled anti-alpha-fetoprotein. Br Med J (Clin Res Ed) (1981) 0.87
Splanchnic, renal, and muscle clearance of alanylglutamine in man and organ fluxes of alanine and glutamine when infused in free and peptide forms. Metabolism (1990) 0.87
Radioimmunodetection of gastrointestinal neoplasms with antibodies to carcinoembryonic antigen. Cancer Res (1980) 0.87
Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System. Eur J Haematol (2007) 0.87
Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopically gained cells from lung cancer patients. Chest (1997) 0.86
Birmingham Medical Research Expeditionary Society 1977 Expedition: serum and urine proteins during a high altitude trek. Postgrad Med J (1979) 0.86
Quantitation of vitronectin in serum: evaluation of its usefulness in routine clinical practice. J Clin Pathol (1993) 0.86
Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages. FEBS Lett (2002) 0.86
Relation of gene expression (allotypes) of the fourth component of complement to insulin dependent diabetes and its microangiopathic complications. Br Med J (Clin Res Ed) (1985) 0.85
IgA subclasses in sputum from patients with bronchiectasis. Respir Med (1990) 0.85
Class II HLA DNA polymorphisms in type 1 (insulin-dependent) diabetic patients of north Indian origin. Diabetologia (1988) 0.85
Identification of the serum binding proteins for iron, zinc, cadmium, nickel, and calcium. Clin Chem (1983) 0.84
Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis. Leukemia (2011) 0.84
Increased serum levels of soluble CD44-isoform v5 in rheumatic diseases are restricted to seropositive rheumatoid arthritis. Acta Med Austriaca (1997) 0.84
The detection of tritium-labeled ligands and their carrier proteins using a multiwire proportional counter. Anal Biochem (1982) 0.84
Propranolol binding to serum orosomucoid. Lancet (1979) 0.84
The HLA-D associations of type 1 (insulin-dependent) diabetes in Punjabi Asians in the United Kingdom. Diabetologia (1987) 0.84
Monoclonal antibodies for in-vivo localization. Lancet (1982) 0.83
Cancer-associated proteins in effusion fluids. J Clin Pathol (1977) 0.83
High-density lipoprotein subfractions measured in stored serum. Clin Chem (1994) 0.83
A paraneoplastic syndrome mimicking extrauterine pregnancy. Ann Oncol (2002) 0.82
Clinical evaluation of anti-alpha-fetoprotein radioimmunodetection. Br J Radiol (1986) 0.82
Multiple myeloma: an update on biology and treatment. Ann Oncol (1999) 0.82
Improved methodology and precision using a straight base line technique for the quantitation of proteins by two dimensional immunoelectrophoresis. Clin Chim Acta (1975) 0.82
Lipoprotein response to a National Cholesterol Education Program step II diet with and without energy restriction. Metabolism (1999) 0.81
Low molecular weight proteinuria in insulin-dependent diabetes. Diabetes Res (1986) 0.81
Synthesis of two components of human complement, beta 1H and C3bINA, during fetal life. Acta Paediatr Scand (1981) 0.81
An arterio-venous study of serum alpha1-antitrypsin in patients with chronic bronchitis. Clin Chim Acta (1978) 0.81
The inter-relationship of thyroid hormones, vitamin A and their binding proteins following acute stress. Clin Endocrinol (Oxf) (1978) 0.81
Immunodetection of 11 beta-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization. Endocrinology (1997) 0.81
HLA-DR and DQ DNA polymorphisms in subjects of Asian Indian and white Caucasian origin. Mol Immunol (1988) 0.81
Subclass typing of IgG paraproteins by immunofixation electrophoresis. Clin Chem (1995) 0.81
Glycylglutamine: metabolism and effects on organ balances of amino acids in postabsorptive and starved subjects. Am J Physiol (1992) 0.80
Immunofluorescence assays (IFA) and enzyme-linked immunosorbent assays (ELISA) in autoimmune disease diagnostics--technique, benefits, limitations and applications. Scand J Clin Lab Invest Suppl (2001) 0.80
Homocysteine and early re-stenosis after carotid eversion endarterectomy. Eur J Vasc Endovasc Surg (2006) 0.80
The inhibition of cathepsin B by plasma haptoglobin biochemistry (enzymes, metabolism). Experientia (1981) 0.80
Hyperdiploidy and apparent aneusomy in mesothelial cells from non-malignant effusions as detected by fluorescence in situ hybridization (FISH). Cytometry (1999) 0.80
Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial. J Thromb Haemost (2011) 0.80
Illusions of tumour killing using radiolabelled antibodies. Lancet (1986) 0.80
Perchlorate blocking for radioimmunodetection. J Nucl Med (1983) 0.80
IgM-expressing Waldenstrom's macroglobulinemia tumor cells reveal a potential for isotype switch events in vivo. Leukemia (2007) 0.80